Current Opinion in Hematology volume 18, issue 3, P158-165 2011 DOI: 10.1097/moh.0b013e32834521dd View full text
|
|
Share
Patrick T McGann, Russell E Ware

Abstract: Purpose of review Sickle cell anemia (SCA) is a well-characterized severe hematological disorder with substantial morbidity and early mortality. Hydroxyurea is a potent inducer of fetal hemoglobin, and evidence over the past 25 years has documented its laboratory and clinical efficacy for both adults and children with SCA. Recent findings The Phase III study of hydroxyurea in infants (BABY HUG) has just been completed and preliminary results indicate equivocal benefits for organ protection during the two-y…

expand abstract